Lundbeck ready to take Genmab antibody to phase II

11 years after having entered into a partnership with Genmab about the antibody treatment for disease in the central nervous system, Lundbeck is now ready to start a phase II trial with a potential treatment for multiple system atrophy (MSA).

After an 11-year collaboration, the Danish alliance between Genmab and Lundbeck has reached another clinical milestone, according to the database Clinical Trials, which collects information about research studies.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading